COVID-19 vaccines

In this radio interview with John Batchelor, our conversation includes (1) the approval of the latest COVID vaccines; and (2) the problem – especially for people in some occupations – with testing for the presence of marijuana and other drugs.
Last week, the FDA and CDC presented their recommendations for the newest round of COVID-19 vaccines. As with everything COVID, there are proponents and detractors, or, putting it another way, both knowledgeable experts and disinformation-spreading attention-seekers. The reality is that a group of experts made a judgment based on actual data.  We discuss the evidence here so you can make your own informed decision.
Two bills – one in Idaho, the other in the U.S. Senate – defy science, logic, and civic responsibility. The first would criminalize the administration of life-saving mRNA vaccines, while the second would ban mask mandates.
We now have both mRNA (Pfizer, Moderna) and vector (AstraZeneca, J&J) vaccines. As we move to boosters, can we – should we – mix and match? Is choosing one from Column A and one from Column B better, worse, or just the same?
Our first two vaccines have greater than 90% efficacy; Novavax reports 89.3%, Johnson and Johnson’s reports 66%. Should we care? What do those numbers mean to you and me when we worry about the protection the vaccine affords us?
The Advisory Committee on Immunization Practices (ACIP) created queue guidelines for those receiving the COVID-19 vaccines. While vaccination of healthcare workers and residents of long-term care facilities is already underway, there's much being written about position jockeying for those in the groups that follow. Let's take a deeper dive into these deliberations.
Eric Topol is a cardiologist working in translational medicine, innovation, at Scripps Clinic in San Diego. He is an active commentator in healthcare. Here is his Twitter thread on Operation Warp Speed along with the vaccine development timeline.